Kurma Partners

Jean-François Rivassou combines engineering training, McKinsey strategy consulting and healthcare operations with eight years leading digital and software growth deals, focusing on late-stage healthcare firms scaling clinical-to-commercial assets.

Alain Horvais leads a diagnostics fund, with a decade in senior roles at Bio‑Rad and AstraZeneca, a PhD in molecular biology, biotechnology management training and panel expertise scaling complex biomarkers.

Amanda Gett, PhD immunologist who worked in Roche global business development and strategy, builds biotech companies by spinning out academic research, reviving deprioritized pharma assets and using a venture studio.

Benjamin Belot is an AI-health/biotech specialist with a biotech degree and INSEAD MBA, experience in high-throughput and data-driven pharma R&D, author of a public digital therapeutics framework and healthtech speaker.

Physician-turned-investor in Munich, Peter Neubeck leverages medical training and an insistence on good data over hype to mentor early-stage academic biotech and bridge German-speaking and pan‑European ecosystems.

Philippe Peltier leverages Bain consulting, L'Oréal and ESSEC to apply a finance- and strategy-led, non-scientific approach to medtech and healthtech (devices, diagnostics, digital health), mentoring founders on French regulatory/commercial matters.

Rémi Droller, a scientist-investor with 25+ years in biotech, spends 1–3 years in Argobio’s studio co‑building and derisking academic teams, engineering cross‑border assets that reach early billion‑dollar exits.

Sylvain Cascarino is a consultant and entrepreneur with experience in finance, organizational improvement, and project management. He served as CFO and partner at Kurma Partners, a healthcare-focused seed and venture capital firm, from 2013 to 2025, and previously held roles as tax adviser at Arthur Andersen, fund controller at LaSalle Investment, and internal auditor at Jones Lang LaSalle. He co-founded le MAG VoD in 2009 and has worked as a freelance consultant in organization and project management.

Thierry Laugel, with 25+ years' experience and a PharmD and PhD in pharmacology plus biotech R&D background, incubates and deliberately grows academic and pharma spin-outs, frugally reaching inflection before co-investors.

Vanessa Malier is an executive with experience in venture capital, biotech, and pharmaceutical industries. She has held roles as investor, executive, board member, and chairman, with involvement in company building, mergers and acquisitions, and business development across early and late-stage healthcare products. She currently serves as a board member at Fondation Pour l'Audition and previously worked at Kurma Partners, where she contributed to the firm's expansion and strategic partnership with Eurazeo.

Hadrien Bouchez keeps a notably low public profile—appearing mainly in deal announcements—and bridges university research and venture capital by evaluating academic and industrial projects alongside tech transfer representatives on panels.